PDCD1 and non-small cell lung carcinoma: Immunotherapies, especially immune checkpoint inhibitors (ICIs) targeting the programmed cell death protein 1 (PD-1)/Programmed Cell Death Ligand 1 (PD-L1) axis, have revolutionized oncology and represents a promising modality for NSCLC (7).